Synlogic Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Synlogic stock.
View analyst ratings for Synlogic or view top-rated stocks.

Wall Street analysts have given Synlogic a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Synlogic wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Synlogic saw a decrease in short interest in May. As of May 28th, there was short interest totaling 405,000 shares, a decrease of 24.9% from the May 13th total of 539,500 shares. Based on an average daily trading volume, of 488,700 shares, the days-to-cover ratio is currently 0.8 days. Approximately 1.1% of the company's stock are short sold.
View Synlogic's Short Interest.

Synlogic is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Synlogic.

Synlogic, Inc. (NASDAQ:SYBX) posted its quarterly earnings results on Thursday, May, 13th. The biotechnology company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.03.
View Synlogic's earnings history.

Synlogic's stock was trading at $1.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SYBX stock has increased by 179.9% and is now trading at $4.31.
View which stocks have been most impacted by COVID-19.

Shares of Synlogic reverse split on the morning of Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

5 equities research analysts have issued 12-month price objectives for Synlogic's shares. Their forecasts range from $10.00 to $15.00. On average, they anticipate Synlogic's share price to reach $13.33 in the next twelve months. This suggests a possible upside of 209.4% from the stock's current price.
View analysts' price targets for Synlogic or view top-rated stocks among Wall Street analysts.

Some companies that are related to Synlogic include Arcturus Therapeutics (ARCT), RAPT Therapeutics (RAPT), Prometheus Biosciences (RXDX), Syndax Pharmaceuticals (SNDX), Evelo Biosciences (EVLO), OrganiGram (OGI), Atossa Therapeutics (ATOS), ADVANZ PHARMA (CXRXF), Merus (MRUS), Collegium Pharmaceutical (COLL), Affimed (AFMD), Karyopharm Therapeutics (KPTI), Zomedica (ZOM), Silence Therapeutics (SLN) and Crinetics Pharmaceuticals (CRNX).
View all of SYBX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL) and Verastem (VSTM).

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

Synlogic's stock is owned by many different institutional and retail investors. Top institutional investors include Ikarian Capital LLC (3.65%), Gilder Gagnon Howe & Co. LLC (3.65%), Dimensional Fund Advisors LP (2.38%), Royce & Associates LP (1.18%), BlackRock Inc. (0.99%) and Renaissance Technologies LLC (0.77%).
View institutional ownership trends for Synlogic.

SYBX stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Morgan Stanley, Renaissance Technologies LLC, Dimensional Fund Advisors LP, Bank of New York Mellon Corp, BlackRock Inc., and Commonwealth Equity Services LLC.
View insider buying and selling activity for Synlogic or view top insider-selling stocks.

SYBX stock was purchased by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Gilder Gagnon Howe & Co. LLC, Royce & Associates LP, Squarepoint Ops LLC, QS Investors LLC, Archford Capital Strategies LLC, Flagship Harbor Advisors LLC, and Janney Montgomery Scott LLC.
View insider buying and selling activity for Synlogic or or view top insider-buying stocks.

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SYBX stock can currently be purchased for approximately $4.31.

Synlogic has a market capitalization of $225.71 million and generates $550,000.00 in revenue each year. The biotechnology company earns $-59,170,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.

Synlogic employs 72 workers across the globe.

The official website for Synlogic is www.synlogictx.com.

Synlogic is headquartered at 301 Binney St. Suite 402, Cambridge MA, 02142.

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]